Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2016
New Zealand Pharmaceutical Schedule - 1 November 2016 update
1 November 2016 - The November 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...
Posted by Michael Wonder on 28 Oct 2016
Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use
28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 27 Oct 2016
New Zealanders to benefit from partnership to enhance responsible use of medicines
27 October 2016 - PHARMAC is pleased to announce a new partnership to support prescribing decisions and promote the responsible ...
Posted by Michael Wonder on 23 Oct 2016
Woman battling rare cancer gets PHARMAC funding for drug
24 October 2016 - A young woman with a body riddled with fast growing tumours, who was left in a ...
Posted by Michael Wonder on 20 Oct 2016
Woman in limbo over rare cancer treatment
21 October 2016 - For 23-year-old Olivia Fryer, three weeks could be everything. ...
Posted by Michael Wonder on 17 Oct 2016
Decision to list cholic acid (Cholebiol) for rare disorder
17 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Max Health Limited for the ...
Posted by Michael Wonder on 17 Oct 2016
Proposal to list enzyme replacement therapies for some rare disorders
17 October 2016 - PHARMAC is seeking feedback on a proposal to list alglucosidase alfa (Myozyme), idursulfase (Elaprase), and laronidase ...
Posted by Michael Wonder on 13 Oct 2016
Breast cancer sufferers' crusade for more medicine
13 October 2016 - Women across the country with advanced breast cancer are joining forces to campaign for better access ...
Posted by Michael Wonder on 13 Oct 2016
PHARMAC publishes Annual Report for the year ending 30 June 2016
13 October 2016 - PHARMAC has published its Annual Report for 2015/6. ...
Posted by Michael Wonder on 12 Oct 2016
Terminal breast cancer patients denied life-extending drugs available in Australia
13 October 2016 - Time is invaluable to terminal breast cancer patient Tamara Malone. ...
Posted by Michael Wonder on 12 Oct 2016
Decision to award sole supply of venlafaxine
12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride ...
Posted by Michael Wonder on 11 Oct 2016
Multi-product proposal involving nine pharmaceuticals
11 October 2016 - PHARMAC is seeking feedback on a proposal to fund three new treatments, widen access to three ...
Posted by Michael Wonder on 11 Oct 2016
Decision regarding funding of the HIV treatments dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa)
11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding ...
Posted by Michael Wonder on 10 Oct 2016
New electronic portal for bidding on PHARMAC’s annual tender
10 October 2016 - New e-portal for PHARMAC’s annual tender now available to trial. ...